Stocks News

LAST PRICE
107.0000
TODAY'S CHANGE (%)
Trending Up12.1400 (12.7978%)

Bid / Lots
105.2000/ 1
Ask / Lots
110.0000/ 9
Open / Previous Close
103.8800 / 94.8600
Day Range
Low 100.9050
High 110.1555
52 Week Range
Low 43.8900
High 110.1555
Volume
2,003,975
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- DJ Blueprint Medicines Shares Hit 52-Week on Strong Ayvakit Sales, from 12 hours ago by Dow Jones
  12 hours ago by Dow Jones
  Companies Mentioned: BPMC
  
  By Colin Kellaher
  
  Blueprint Medicines shares rose more than 10% and hit a new 52-week high on Thursday after the precision-therapy company posted better-than-expected quarterly sales for its Ayvakit franchise and raised its full-year guidance.
- Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating, from 13 hours ago by MT Newswires
  13 hours ago by MT Newswires
  Companies Mentioned: BPMC
  10:56 AM EDT, 05/02/2024 (MT Newswires) -- Blueprint Medicines (BPMC) has an average rating of outperform and price targets ranging from $50 to $130, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic res...
- Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises, from 13 hours ago by MT Newswires
  13 hours ago by MT Newswires
  Companies Mentioned: BPMC
  10:16 AM EDT, 05/02/2024 (MT Newswires) -- Blueprint Medicines (BPMC) shares were up about 13% in recent trading on Thursday, after the company reported Q1 earnings against analysts' expectations of a loss. The company reported Q1 net income of $1.4...
- DJ Blueprint Medicines Price Target Maintained With a $97.00/Share by Needham, from 16 hours ago by Dow Jones
  16 hours ago by Dow Jones
  Companies Mentioned: BPMC
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/BPMC/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 02, 2024 08:03 ET (12:03 GMT)
- -- Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M, from 16 hours ago by MT Newswires
  16 hours ago by MT Newswires
  Companies Mentioned: BPMC
  07:15 AM EDT, 05/02/2024 (MT Newswires) -- ...

Yesterday
- ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types, from 8 hours ago by Business Wire
  8 hours ago by Business Wire
  Companies Mentioned: IBRX
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 8 hours ago by GlobeNewswire
  8 hours ago by GlobeNewswire
  Companies Mentioned: CYTK
May 1, 2024
- Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024, from 4:06PM ET on Wednesday May 01, 2024 by GlobeNewswire
  4:06PM ET on Wednesday May 01, 2024 by GlobeNewswire
  Companies Mentioned: RVMD
- Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050, from 10:05AM ET on Wednesday May 01, 2024 by CNW Group
  10:05AM ET on Wednesday May 01, 2024 by CNW Group
  Companies Mentioned: BVAXF, MGNX, BOLD, IBRX
- Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, from 7:00AM ET on Wednesday May 01, 2024 by GlobeNewswire
  7:00AM ET on Wednesday May 01, 2024 by GlobeNewswire
  Companies Mentioned: APLS
Apr 30, 2024
- ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA(R) Approval in Fireside Chat at the Annual Conference of the American Urological Association, from 8:00AM ET on Tuesday Apr 30, 2024 by Business Wire
  8:00AM ET on Tuesday Apr 30, 2024 by Business Wire
  Companies Mentioned: IBRX
- Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline, from 6:49AM ET on Tuesday Apr 30, 2024 by MT Newswires
  6:49AM ET on Tuesday Apr 30, 2024 by MT Newswires
  Companies Mentioned: MSTR, NVDA, TSLA, AAPL, AMZN, META, DJT, IBRX
Apr 29, 2024
- Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress, from 4:00PM ET on Monday Apr 29, 2024 by GlobeNewswire
  4:00PM ET on Monday Apr 29, 2024 by GlobeNewswire
  Companies Mentioned: CYTK
- --Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating, from 11:01AM ET on Monday Apr 29, 2024 by MT Newswires
  11:01AM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: IBRX
- --Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $52 From $60, Maintains Neutral Rating, from 7:19AM ET on Monday Apr 29, 2024 by MT Newswires
  7:19AM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: APLS

Blueprint Medicines Corp
NASDAQ:BPMCUnited States

Search Criteria

Yesterday

DJ Blueprint Medicines Shares Hit 52-Week on Strong Ayvakit Sales, from 12 hours ago by Dow Jones

Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating, from 13 hours ago by MT Newswires

Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises, from 13 hours ago by MT Newswires

DJ Blueprint Medicines Price Target Maintained With a $97.00/Share by Needham, from 16 hours ago by Dow Jones

-- Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M, from 16 hours ago by MT Newswires

Peers Headlines

Yesterday

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types, from 8 hours ago by Business Wire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 8 hours ago by GlobeNewswire

May 1, 2024

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024, from 4:06PM ET on Wednesday May 01, 2024 by GlobeNewswire

Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050, from 10:05AM ET on Wednesday May 01, 2024 by CNW Group

Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, from 7:00AM ET on Wednesday May 01, 2024 by GlobeNewswire

Apr 30, 2024

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA(R) Approval in Fireside Chat at the Annual Conference of the American Urological Association, from 8:00AM ET on Tuesday Apr 30, 2024 by Business Wire

Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline, from 6:49AM ET on Tuesday Apr 30, 2024 by MT Newswires

Apr 29, 2024

Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress, from 4:00PM ET on Monday Apr 29, 2024 by GlobeNewswire

--Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating, from 11:01AM ET on Monday Apr 29, 2024 by MT Newswires

--Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $52 From $60, Maintains Neutral Rating, from 7:19AM ET on Monday Apr 29, 2024 by MT Newswires